TPST

SEC source: 0001213900-26-106400 · ownership.xml · derivative · entry 1

Smith Nancy Freda · CIK 0002019811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2036-09-22

F1 · derivative.exercise_date: The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

SEC source: 0001193125-26-262257 · ownership.xml · derivative · entry 1

Richey William Drake · CIK 0002139522 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

SEC source: 0001193125-26-274545 · ownership.xml · derivative · entry 1

Yee John D. · CIK 0001926290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

SEC source: 0001947673-26-000002 · form4-04022026_050423.xml · derivative · entry 1

Trojanowski Justin · CIK 0001947673 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2036-03-30

F1 · derivative.exercise_date: This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.

SEC source: 0001871423-26-000002 · form4-04022026_050421.xml · derivative · entry 1

Maestas Nicholas · CIK 0001871423 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2036-03-30

F1 · derivative.exercise_date: This option shall vest with respect to 25% of the total number of shares underlying the option on March 31, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.

SEC source: 0001931356-26-000011 · form4-03252026_090332.xml · nonDerivative · entry 1

Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Factor Bioscience Inc.

Disclosed balance after: 231,482

F1 · ownership.nature: The shares are held by Factor Bioscience Inc. ("Factor"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001193125-26-279703 · ownership.xml · derivative · entry 3

Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Factor Bioscience Inc.

Disclosed balance after: 231,482

Underlying: Common Stock · 231,482 shares

Expires not disclosed

F1 · kind: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.

F2 · price: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.

F5 · derivative.exercise_date: The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval.

F5 · derivative.expiration_date: The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval.

F3 · ownership.nature: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.

SEC source: 0001193125-26-279703 · ownership.xml · derivative · entry 2

Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Factor Bioscience Inc.

Disclosed balance after: 231,482

Underlying: Common Stock · 231,482 shares

Expires not disclosed

F1 · kind: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.

F2 · price: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.

F4 · derivative.exercise_date: The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.

F4 · derivative.expiration_date: The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.

F3 · ownership.nature: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.

SEC source: 0001193125-26-279703 · ownership.xml · nonDerivative · entry 1

Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Factor Bioscience Inc.

Disclosed balance after: 231,482

F2 · price: The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.

F1 · acquired: On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.

F3 · ownership.nature: The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.

SEC source: 0001931356-26-000006 · form4-02062026_090210.xml · derivative · entry 1

Angel Matthew · CIK 0001931356 · Director · CEO and President · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 269,621

Underlying: Common Stock · 269,621 shares

Expires 2036-02-03

F1 · derivative.exercise_date: This option shall vest with respect to 25% of the total number of shares underlying the option on February 4, 2027 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service.

SEC source: 0001127430-26-000002 · form4-01282026_040103.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,230

Underlying: Common Stock · 1,230 shares

Expires 2036-01-26

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001871563-26-000002 · form4-01282026_040107.xml · derivative · entry 1

Simantov Ronit · CIK 0001871563 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,230

Underlying: Common Stock · 1,230 shares

Expires 2036-01-26

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001214505-26-000003 · form4-01282026_040101.xml · derivative · entry 1

NICHOL GEOFFREY · CIK 0001214505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,230

Underlying: Common Stock · 1,230 shares

Expires 2036-01-26

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001321402-26-000003 · form4-01282026_040105.xml · derivative · entry 1

RAAB MICHAEL · CIK 0001321402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,230

Underlying: Common Stock · 1,230 shares

Expires 2036-01-26

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-25-000807 · form4-01062025_050116.xml · derivative · entry 1

Brady Stephen R · CIK 0001606241 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 550,000

Underlying: Common Stock · 550,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.

SEC source: 0001415889-25-000806 · form4-01062025_050114.xml · derivative · entry 1

Whiting Samuel · CIK 0001870373 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 270,000

Underlying: Common Stock · 270,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.

SEC source: 0001415889-25-000808 · form4-01062025_050118.xml · derivative · entry 1

Trojanowski Justin · CIK 0001947673 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.

SEC source: 0001415889-25-000805 · form4-01062025_050112.xml · derivative · entry 1

Maestas Nicholas · CIK 0001871423 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.

SEC source: 0000950170-24-095675 · ownership.xml · nonDerivative · entry 2

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,941

F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F2 · ownership.direct: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

SEC source: 0000950170-24-095675 · ownership.xml · nonDerivative · entry 1

Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner

Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner

Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner

Versant Vantage II, L.P. · CIK 0001832235 · 10% owner

Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner

Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 597,940

F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.35 to $1.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · ownership.direct: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

SEC source: 0001415889-24-019339 · form4-07082024_040701.xml · nonDerivative · entry 1

Brady Stephen R · CIK 0001606241 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,376

F1 · balance_after: Includes 11,376 shares acquired under the Issuer's stock purchase plan.

SEC source: 0001415889-24-019279 · form4-07032024_110739.xml · nonDerivative · entry 1

Whiting Samuel · CIK 0001870373 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,573

F1 · balance_after: Includes 3,000 shares acquired under the Issuer's stock purchase plan.

SEC source: 0001415889-24-018866 · form4-07022024_040706.xml · nonDerivative · entry 1

Trojanowski Justin · CIK 0001947673 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,168

F1 · balance_after: Includes 14,668 shares acquired under the Issuer's stock purchase plan.

SEC source: 0001415889-24-017012 · form4-06142024_060608.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017010 · form4-06142024_060603.xml · derivative · entry 1

Simantov Ronit · CIK 0001871563 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017011 · form4-06142024_060605.xml · derivative · entry 1

NICHOL GEOFFREY · CIK 0001214505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017009 · form4-06142024_060601.xml · derivative · entry 1

RAAB MICHAEL · CIK 0001321402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-24-001040 · doc4.xml · derivative · entry 1

Brady Stephen R · CIK 0001606241 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-01-02

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service.

SEC source: 0001209191-24-001038 · doc4.xml · derivative · entry 1

Whiting Samuel · CIK 0001870373 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-01-02

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service.

SEC source: 0001209191-24-001036 · doc4.xml · derivative · entry 1

Trojanowski Justin · CIK 0001947673 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,500

Underlying: Common Stock · 26,500 shares

Expires 2034-01-02

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service.

SEC source: 0001209191-24-001035 · doc4.xml · derivative · entry 1

Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-01-02

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service.

SEC source: 0001209191-23-052783 · doc4.xml · derivative · entry 1

Brady Stephen R · CIK 0001606241 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 725,000

Underlying: Common Stock · 725,000 shares

Expires 2033-10-10

F1 · derivative.exercise_date: 25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.

SEC source: 0001209191-23-052782 · doc4.xml · derivative · entry 1

Trojanowski Justin · CIK 0001947673 · Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2033-10-10

F1 · derivative.exercise_date: 25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.

SEC source: 0001209191-23-052781 · doc4.xml · derivative · entry 1

Whiting Samuel · CIK 0001870373 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,000

Underlying: Common Stock · 325,000 shares

Expires 2033-10-10

F1 · derivative.exercise_date: 25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.

SEC source: 0001209191-23-052780 · doc4.xml · derivative · entry 1

Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-10-10

F1 · derivative.exercise_date: 25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.

SEC source: 0001209191-23-038443 · doc4.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock · 8,200 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-23-038440 · doc4.xml · derivative · entry 1

Simantov Ronit · CIK 0001871563 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock · 8,200 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-23-038448 · doc4.xml · derivative · entry 1

NICHOL GEOFFREY · CIK 0001214505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock · 8,200 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-23-038453 · doc4.xml · derivative · entry 1

RAAB MICHAEL · CIK 0001321402 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock · 8,200 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-23-002146 · doc4.xml · derivative · entry 1

Dubensky Thomas W. · CIK 0001635590 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,700

Underlying: Common Stock · 102,700 shares

Expires 2033-01-02

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

SEC source: 0001209191-23-002141 · doc4.xml · derivative · entry 1

Trojanowski Justin · CIK 0001947673 · Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,300

Underlying: Common Stock · 20,300 shares

Expires 2033-01-02

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

SEC source: 0001209191-23-002148 · doc4.xml · derivative · entry 1

Whiting Samuel · CIK 0001870373 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,700

Underlying: Common Stock · 69,700 shares

Expires 2033-01-02

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

SEC source: 0001209191-23-002142 · doc4.xml · derivative · entry 1

Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,425

Underlying: Common Stock · 38,425 shares

Expires 2033-01-02

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

SEC source: 0001209191-23-002144 · doc4.xml · derivative · entry 1

Brady Stephen R · CIK 0001606241 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,300

Underlying: Common Stock · 177,300 shares

Expires 2033-01-02

F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.

SEC source: 0001209191-22-052025 · doc4.xml · derivative · entry 1

Trojanowski Justin · CIK 0001947673 · Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 2,500 shares

Expires 2032-10-02

F1 · derivative.exercise_date: The shares underlying the option will vest in 48 equal monthly installments commencing on November 3, 2022, subject to the Reporting Person's continuous service through each vesting date.

SEC source: 0001179110-22-003402 · edgar.xml · derivative · entry 1

Lorenzo Pierre · CIK 0001869915 · Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,477

Underlying: Common Stock · 8,477 shares

Expires 2032-06-20

F1 · derivative.exercise_date: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

SEC source: 0001179110-22-003399 · edgar.xml · derivative · entry 1

Dubensky Thomas W. · CIK 0001635590 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,801

Underlying: Common Stock · 87,801 shares

Expires 2032-06-20

F1 · derivative.exercise_date: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

SEC source: 0001179110-22-003401 · edgar.xml · derivative · entry 1

Maestas Nicholas · CIK 0001871423 · VP of Strategy and Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,270

Underlying: Common Stock · 51,270 shares

Expires 2032-06-20

F1 · derivative.exercise_date: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

SEC source: 0001179110-22-003400 · edgar.xml · derivative · entry 1

Whiting Samuel · CIK 0001870373 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,680

Underlying: Common Stock · 55,680 shares

Expires 2032-06-20

F1 · derivative.exercise_date: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

SEC source: 0001179110-22-003398 · edgar.xml · derivative · entry 1

Brady Stephen R · CIK 0001606241 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,533

Underlying: Common Stock · 173,533 shares

Expires 2032-06-20

F1 · derivative.exercise_date: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.